Vasculitis Patients to Discuss New Treatment Needs
A virtual forum on November 20 will allow patients to share experiences with regulators to advocate for new, non-steroid options.
Updated on Oct. 31, 2026 in Asthma
Live Poll
Do you believe patient input is sufficient to drive meaningful changes in national healthcare treatment access?
The Vasculitis Foundation will host a two-hour virtual listening session on November 20, 2026, to gather patient perspectives for federal regulators. This forum aims to highlight the unmet needs of individuals managing the nearly 20 rare diseases classified as vasculitis.
Why it matters
Current treatment options for vasculitis are limited, with patients often relying on corticosteroids as a primary approach despite their side effects. This session seeks to demonstrate the need for expanded, non-steroid therapies to policymakers and the FDA.
The Vasculitis Foundation reports there are approximately 10 FDA-approved therapies available for the nearly 20 rare diseases encompassed by vasculitis. Future implications for treatment access remain unknown until the foundation completes its planned whitepaper.
The players
Vasculitis Foundation
A national patient advocacy organization dedicated to supporting research and awareness for nearly 20 rare inflammatory blood vessel diseases.
Wendy K.D. Selig
A health sector strategy expert who will facilitate the upcoming community listening session.
The details
Vasculitis involves the inflammation of blood vessels, which can cause significant organ damage if left untreated. Corticosteroids are frequently used to suppress this inflammation, but they often lead to long-term health complications. The virtual forum is designed to give patients a platform to share their experiences with regulators and members of Congress, illustrating why new, targeted, non-steroid treatment options are necessary for daily quality of life.
Timeline
The virtual forum will take place on November 20, 2026, from 12:00 PM to 2:00 PM ET.
Health Landscape
This session follows the structure of the FDA Patient-Focused Drug Development initiative to prioritize patient voice in regulatory decisions. It marks a push to move treatment standards beyond traditional steroids toward more advanced, targeted medical interventions.
Patients with vasculitis may find this forum an opportunity to understand how their treatment experiences contribute to broader policy discussions. Those interested in the current state of care should consult their rheumatologist to discuss whether their specific treatment plan aligns with the latest therapeutic advancements.
The takeaway
Vasculitis patients often face a limited treatment landscape dominated by steroids that may have significant long-term side effects. It is a valuable habit to track your current symptoms and side-effect profile so you can have an informed conversation with your physician about new research.
What happens next
The Vasculitis Foundation plans to release a whitepaper summarizing the insights gathered during the November 20, 2026, virtual forum.
Further reading
Learn more about managing inflammatory respiratory and vascular conditions in our Asthma section.
More information
To register for the upcoming session or learn more, visit the forum registration and information page.
Source note: This article includes information reported by Pantagraph.
Live Poll
Do you believe patient input is sufficient to drive meaningful changes in national healthcare treatment access?
